"We are pleased to be presenting the results from our ongoing drug delivery development programs at this year's ARVO Meeting," said Paul Lopez, president of SurModics' Ophthalmology Division. "SurModics' continues to make significant progress with innovative drug delivery systems for the treatment of back-of-the eye diseases. The continued clinical development of the I-vation(TM) TA intravitreal implant product and our work with biodegradable drug delivery systems for both large and small molecules will be highlighted at this meeting."
The poster # 3501/A590 entitled I-vation(TM) TA: 15-Month Clinical Results of the Phase I Safety and Preliminary Efficacy Study, is to be presented on Tuesday, April 29, 2008 at 3:00 PM (EDT) and includes 15- and 18-month clinical data results from the Phase I clinical trial which is evaluating the I-vation intravitreal implant with triamcinoclone acetonide in patients with Diabetic Macular Edema (DME).
The poster # 3183/D916 entitled Long-Term Protein Stability in a Biodegradable Polysaccharide Drug Delivery Implant, to be presented Tuesday, April 29, 2008 at 11:15 AM (EDT), presents data from a pre-clinical study designed to demonstrate stabilization of bioactive protein in a degradable polysaccharide matrix system designed for sustained, controlled release of therapeutic agents into the vitreous.
The paper #5004 entitled Hydrophobic Biodegradable Polysaccharide Implant for Controlled Drug Delivery, to be presented Thursday, May 1, 2008 at 8:45 AM (EDT), highlights results from a study demonstrating controlled in-vitro and in-vivo sustained release of a small molecule from a biodegradable polysaccharide ocular implant.
About SurModics, Inc.
SurModics, Inc. is a leading provider of surface modification and drug delivery technologies to the healthcare industry. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to develop and commercialize innovative products that result in improved patient outcomes. Core offerings include: drug delivery technologies (coatings, microparticles, and implants); surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities; and components for in vitro diagnostic test kits and specialized surfaces for cell culture and microarrays. Collaborative efforts include a sustained drug delivery system in human trials for treatment of retinal disease and the drug delivery polymer matrix on the first-to-market drug-eluting coronary stent. SurModics is headquartered in Eden Prairie, Minnesota and its Brookwood Pharmaceuticals subsidiary is located in Birmingham, Alabama. For more information about the company, visit www.surmodics.com. The content of SurModics' website is not part of this release or part of any filings the company makes with the SEC.
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements. Statements that are not historical or current facts, including statements about beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including the following: (1) realizing the full potential benefits of the company's agreement with Merck & Co., Inc. requires the development of new products and applications of technology; (2) costs or difficulties relating to the integration of the businesses of Brookwood Pharmaceuticals and BioFX Laboratories with SurModics' business may be greater than expected and may adversely affect the company's results of operations and financial condition; (3) developments in the regulatory environment, as well as market and economic conditions, and our reliance on third parties, may adversely affect our business operations and profitability, and the company's ability to achieve our fiscal 2008 corporate goals and to realize the potential of our pipeline; and (4) other factors identified under "Risk Factors" in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2007, and updated in our subsequent reports filed with the SEC. These reports are available in the Investors section of our website at www.surmodics.com and at the SEC website at www.sec.gov. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them in light of new information or future events.
SOURCE: SurModics, Inc.
Maggie Knack, 952-829-2700
Director, Investor Relations